Zetagen Therapeutics, Inc. Receives Patents for Methods in Stimulating Bone Growth Using Small-Molecule

• U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions
• Latest patent issuance furthers the Company’s Global IP strategy
• Company’s intellectual property pipeline targets other oncologic treatments for Skeletal-Related Events (SRE’s) and osteologic interventions

February 19, 2019– (Syracuse, New York) - Zetagen Therapeutics, Inc., a private, US-based biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and orthopedic interventions, announced today that the U.S. Patent and Trademark Office (“USPTO”) has issued U.S. Patent No. 10208306 and the South African Patent Office issued PCT. 2017/00029 to the Company. These patents, entitled Composition and Methods to Promote Bone Formation, include claims covering the use of methods for stimulating bone growth using its novel molecular pathway, ZetaMet™ (Zeta-BC-003). ZetaMet™ (Zeta-BC-003) is a synthetic, small molecule, inductive biologic, delivered via a drug-eluting implant on an osteopromotive carrier.

“These new patent issuances are an important step forward towards our ultimate goal of obtaining the global, commercial rights for our treatments,” said Joe C. Loy, CEO of Zetagen Therapeutics, Inc. “We believe in the potential our therapies hold for patients around the world who live with debilitating metastatic bone cancers.”

The new patent is part of an expanding and comprehensive portfolio of patents, patent applications and other intellectual property covering the composition, synthesis, manufacturing, formulations and uses for the treatment of a variety of metastatic bone lesions and osteologic interventions. Zetagen exclusively licensed its platform technology from the State University of New York in 2016.